Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity. - Wikidata - wikimedia - TriplyDB

Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity.

Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity.

http://www.wikidata.org/entity/Q39062384

about

Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro.FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line.Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells.Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications.Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157.Traf2- and Nck-interacting kinase (TNIK) is involved in the anti-cancer mechanism of dovitinib in human multiple myeloma IM-9 cells.Distribution of Vascular Patterns in Different Subtypes of Renal Cell Carcinoma. A Morphometric Study in Two Distinct Types of Blood Vessels.

P2860

Q33563281-C63F2F46-AECD-45C6-8FF8-518BCAFA2468 Q36909540-2A2C64C4-E0CE-45D1-BEEE-701DD5920898 Q36983860-B0F41D4C-DC65-49C9-B97F-C8FFAF54E791 Q37708933-439F5A89-7460-48A2-9DB5-4DEEC988F9BA Q38656760-D150F2E0-F267-42B1-8CE8-F2C9F17F2F5C Q41092608-45BFBD44-E965-413C-B6E8-BAD89DD79755 Q42108610-CF539CF2-B853-4FC7-993B-C2D946E4160A Q44640459-A5038E52-FF3A-4E7A-8E77-15E869948A1F Q52815341-3B25EA5B-15BB-46BF-99D3-094A292051C6 Q53142724-B8DEBFFD-4401-40C5-8C45-189C85A63C07 Q54046985-F374A032-5BC5-4F85-AE2B-4631306DA8CD

P2860

Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity.

http://www.wikidata.org/entity/Q39062384

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Dovitinib (CHIR258, TKI258): s ...... linical and clinical activity.

@en

Dovitinib (CHIR258, TKI258): s ...... linical and clinical activity.

@nl

type

label

Dovitinib (CHIR258, TKI258): s ...... linical and clinical activity.

@en

Dovitinib (CHIR258, TKI258): s ...... linical and clinical activity.

@nl

prefLabel

Dovitinib (CHIR258, TKI258): s ...... linical and clinical activity.

@en

Dovitinib (CHIR258, TKI258): s ...... linical and clinical activity.

@nl

P1433

Q39062384-E64C8B11-0C3B-438B-8E00-AE0A788F042F

P1476

Q39062384-A3EC03DB-FDAC-4C38-B7B5-F942F5069B4B

P2093

Q39062384-996D3269-BC52-4B9C-AB4D-BF02C0FEFCC9

Q39062384-BC393549-37E6-40E7-B7EE-2FD6CEE2197A

Q39062384-F3FCD1A1-89B7-47C1-B8B4-D1B9DA0D39EA

P2860

Q39062384-000D8CAE-201E-475E-BB1B-216CE82F7ECB

Q39062384-0851A835-ACAD-499A-B991-1FB758AD858F

Q39062384-0E83FC16-D275-43B9-9248-7509FB5F8A70

Q39062384-0F632765-2F54-4405-9C63-13C04D79806A

Q39062384-172AFDC6-F582-4423-85E1-1E163848948B

Q39062384-27124AE7-177A-4FD4-A711-13B4DE8C9E0A

Q39062384-2A9E566C-32A4-4330-842C-651DA572FFFC

Q39062384-2F472680-BCF8-47BD-AE26-B204D9493BA7

Q39062384-35AD4676-6CEE-4F69-8FFC-CC3C6633F9CA

Q39062384-3700B0CC-0077-4D0C-9898-5BAED43CDA85

P304

Q39062384-40949698-2748-444E-8B16-DC92580C359F

P31

Q39062384-37CD4CEF-C3DE-4D55-AE89-4AA2A384A377

P356

Q39062384-6BF3EC5C-132F-4181-9A50-E96FE438FD5D

P407

Q39062384-69A72E2B-6177-4508-87E5-359258C7CDB9

P433

Q39062384-7BF2FF47-E2C8-4C9F-87F2-2C19C9B9A8D3

P478

Q39062384-D2580597-58B8-4CBE-A958-BD3BC398A03B

P50

Q39062384-A0266A19-628D-481E-939D-32B74ED00E54

P577

Q39062384-644B8E3A-9A18-4E7D-B23C-7C78D184C74D

P698

Q39062384-7F7E4FFF-1B45-4590-9A5D-8A728B86CB4C

P356

P1433

Future Oncology

P1476

Dovitinib (CHIR258, TKI258): s ...... linical and clinical activity.

@en

P2093

Chiara Paglino

http://www.w3.org/2001/XMLSchema#string

Palma Giglione

http://www.w3.org/2001/XMLSchema#string

Wanda Liguigli

http://www.w3.org/2001/XMLSchema#string

P2860

Fibroblast growth factors

Hypoxia-inducible factors and the response to hypoxic stress

Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.

Cross-talk of WNT and FGF signaling pathways at GSK3beta to regulate beta-catenin and SNAIL signaling cascades

FGF receptors: cancer biology and therapeutics

Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology

FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features

Patterns of somatic mutation in human cancer genomes

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.

P304

39-50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.14.208

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25572783

http://www.w3.org/2001/XMLSchema#string